Market Overview

Analyst Points Out Sarepta Mgmt Has Not Adjusted Outlook for Eteplirsen's Breakthrough Designation

Barron's Recap: 16 All-Star Women Financial Advisors
Here's Why Sarepta Is Skyrocketing While BioMarin Is Falling
BioMarin Drug's Future In Doubt After FDA Panel Vote (Investor's Business Daily)

Shares of Sarepta (NASDAQ: SRPT) bounced into positive territory about an hour into Wednesday's morning session as traders responded to a Bloomberg interview with Baird's Brian Skorney.

Contrasting an earlier view from Deutsche Bank's Robyn Karnauskas, Skorney assured Sarepta has not yet changed its guidance for the breakthrough designation on eteplirsen. The analyst noted Sarepta management has said it will deciding on a strategy for eteplirsen over the next few months.

Skorney currently rates Sarpeta at Outperform with a $63 price target.

Sarepta shares have continued higher since pushing into positive territory. The stock is up more than 1.8 percent to $40.47 at last check.

Latest Ratings for SRPT

Nov 2015Leerink SwannMaintainsMarket Perform
Oct 2015JefferiesInitiates Coverage onHold
Oct 2015WedbushUpgradesNeutralOutperform

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings


Related Articles (SRPT)

View Comments and Join the Discussion!

Get Benzinga's Newsletters